Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
November 11, 2016
"This latest presentation shows that our proprietary core protein allosteric modulators (CpAMs) have unique antiviral properties, including the critical ability to stop the formation of new cccDNA," said
Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers (CpAMs)
November 14, 2016from 12:00 PM to 1:30 PM
- Presented by:
Richard Colonno, PhD, and Qi Huang, PhD, Director of Biology
- Summary: Assembly has developed a proprietary series of CpAM compounds that can both suppress viral replication and inhibit the formation of cccDNA in HBV cell infection assays. In comparison, nucleos(t)ide therapy, such as the the current HBV standard of care drug entecavir, can efficiently block viral replication but has only a modest impact on cccDNA levels.
Poster #1897 can be viewed at the events section at the company's website or at www.liverlearning.org.
gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. For more information, visit assemblybio.com.
The information in this press release contains estimates and other
forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of our HBV-cure program, timing of the initiation of and availability of data from our ongoing and planned clinical trials, and plans, strategies, and intentions related to our programs. Certain forward looking statements may be identified by reference to a future period or periods or by use of forward-looking terminology such as "developing," "potential," "projected," "anticipated," "positioned," "strategy," "should" or "may." Such forward-looking statements, which we intend to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include, among others: preclinical models may not be representative of disease behavior in clinical studies; our ability to retain necessary employees and to staff our operations appropriately; the components, timing, cost and results of clinical trials and other development activities involving our product candidates; the unpredictability of the preclinical and clinical development of our product candidates and of the duration and results of regulatory review of those candidates by the
that could cause actual results to differ from the results predicted are more fully detailed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended
publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Assembly Biosciences, Inc. Lauren Glaserlglaser@assemblybio.com Media: Barbara Lindheimbarbara@assemblybio.com 212 584-2276
News Provided by Acquire Media
« back to news page